Literature DB >> 26154481

Percutaneous Cryoablation vs Partial Nephrectomy: Cost Comparison of T1a Tumors.

Monzer Chehab1, Joshua A Friedlander1, Jeremy Handel1, Stephen Vartanian1, Anant Krishnan2, Ching-Yee Oliver Wong2, Howard Korman3, Brian Seifman3, Joseph Ciacci1.   

Abstract

PURPOSE: To compare cost of percutaneous cryoablation vs open and robot-assisted partial nephrectomy of T1a renal masses from the hospital perspective.
MATERIALS AND METHODS: We retrospectively compared cost, clinical and tumor data of 37 percutaneous cryoablations to 26 open and 102 robot-assisted partial nephrectomies. Total cost was the sum of direct and indirect cost of procedural and periprocedural variables. Clinical data included demographics, Charlson Comorbidity Index (CCI), hospitalization time, complication rate, ICU admission rate, and 30-day readmission rates. Tumor data included size, RENAL nephrometry score, and malignancy rate. Student's t-test was used for continuous variables and Fisher's exact or chi-square tests for categorical data.
RESULTS: Mean total cost was lower for percutaneous cryoablation than open or robot-assisted partial nephrectomy: $6067 vs $11392 or $11830 (p<0.0001) with lower cost of procedure room: $1516 vs $3272 or $3254 (p<0.0001), room and board: $95 vs $1907 or $1106 (p<0.0001), anesthesia: $684 vs $1223 or $1468 (p<0.0001), and laboratory/pathology fees: $205 vs $804 or $720 (p<0.0001). Supply and device cost was higher than open: $2596 vs $1352 (p<0.0001), but lower than robot-assisted partial nephrectomy: $3207 (p=0.002). Mean hospitalization times were lower for percutaneous cryoablation (p<0.0001), while age and CCI were higher (p<0.0001). No differences in tumor size, nephrometry score, malignancy rate complication, ICU, or 30-day readmission rates were observed.
CONCLUSION: Percutaneous cryoablation can be performed at significantly lower cost than open and robotic partial nephrectomies for similar masses.

Entities:  

Mesh:

Year:  2015        PMID: 26154481     DOI: 10.1089/end.2015.0183

Source DB:  PubMed          Journal:  J Endourol        ISSN: 0892-7790            Impact factor:   2.942


  8 in total

Review 1.  Focal ablation therapy for renal cancer in the era of active surveillance and minimally invasive partial nephrectomy.

Authors:  Serge Ginzburg; Jeffrey J Tomaszewski; Alexander Kutikov
Journal:  Nat Rev Urol       Date:  2017-09-12       Impact factor: 14.432

2.  Partial nephrectomy versus ablative techniques for small renal masses: a systematic review and network meta-analysis.

Authors:  Johannes Uhlig; Arne Strauss; Gerta Rücker; Ali Seif Amir Hosseini; Joachim Lotz; Lutz Trojan; Hyun S Kim; Annemarie Uhlig
Journal:  Eur Radiol       Date:  2018-09-25       Impact factor: 5.315

Review 3.  Renal cryoablation - a practical guide for interventional radiologists.

Authors:  Matthew Seager; Shankar Kumar; Emma Lim; Graham Munneke; Steve Bandula; Miles Walkden
Journal:  Br J Radiol       Date:  2020-09-22       Impact factor: 3.039

4.  The Money Time for Decision-making.

Authors:  Julien Garnon
Journal:  Cardiovasc Intervent Radiol       Date:  2021-03-22       Impact factor: 2.740

5.  High-Frequency Jet Ventilation During Cryoablation of Small Renal Tumours.

Authors:  Thea Buchan; Miles Walkden; Kathryn Jenkins; Pervez Sultan; Steve Bandula
Journal:  Cardiovasc Intervent Radiol       Date:  2018-03-07       Impact factor: 2.740

Review 6.  Cryoablation versus Partial Nephrectomy for Clinical Stage T1 Renal Masses: A Systematic Review and Meta-Analysis.

Authors:  Wen Deng; Luyao Chen; Yibing Wang; Xiaoqiang Liu; Gongxian Wang; Weipeng Liu; Cheng Zhang; Xiaochen Zhou; Yu Li; Bin Fu
Journal:  J Cancer       Date:  2019-01-29       Impact factor: 4.207

7.  Difference of opinion - Which is the best treatment on a 2 cm complete endophitic tumor on the posterior side of the left kidney? Opinion: Cryoablation.

Authors:  Rodrigo Gobbo Garcia
Journal:  Int Braz J Urol       Date:  2016 Jan-Feb       Impact factor: 1.541

Review 8.  Applications of Focused Ultrasound in the Treatment of Genitourinary Cancers.

Authors:  John Panzone; Timothy Byler; Gennady Bratslavsky; Hanan Goldberg
Journal:  Cancers (Basel)       Date:  2022-03-17       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.